The ingredients of India’s biopharma ambitions

The Hindu online

www.thehindu.com

The COVID-19 pandemic was a watershed moment for our country. While the pharmaceutical sector was robust, it lacked the capacity to produce specialised molecular components at scale. At the start of 2020, nearly all of the 20-plus reagents and enzymes required for making the vaccine kits were import